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Abstract (word count 300) 
Objectives 
Current musculoskeletal outcome tools are fragmented across different healthcare settings and 
conditions. Our objectives were to develop and validate a single musculoskeletal outcome measure 
for use throughout the pathway and patients with different musculoskeletal conditions: the 
Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ).  
Setting 
A consensus workshop with stakeholders from across the musculoskeletal community, workshops 
and individual interviews with a broad mix of musculoskeletal patients identified and prioritised 
outcomes for MSK-HQ inclusion. Initial psychometric validation was conducted in four cohorts from 
community physiotherapy, and secondary care orthopaedic hip, knee and shoulder clinics.  
Participants 
Stakeholders (n=29) included primary care, physiotherapy, orthopaedic and rheumatology patients 
(n=8); general practitioners, physiotherapists, orthopaedists, rheumatologists and pain specialists 
(n=7), patient and professional national body representatives (n=10), and researchers (n=4). The 
four validation cohorts included 570 participants (n=210 Physiotherapy, n=150 Hip, n=150 Knee, 
n=60 Shoulder patients).  
Outcome measures 
Outcomes included the MSK-HQ’s acceptability, feasibility, comprehension, readability, and 
responder burden. The validation cohort outcomes were the MSK-HQ’s completion rate, test-retest 
reliability and convergent validity with reference standards (EQ-5D-5L, Oxford Hip, Knee, Shoulder 
Scores, and the Keele MSK-PROM).  
Results 
Musculoskeletal domains prioritised were: pain severity, physical function, work interference, social 
interference, sleep, fatigue, emotional health, physical activity, independence, understanding, 
confidence to self-manage, and overall-impact. Patients reported MSK-HQ items to be ‘highly 
relevant’, and ‘easy to understand’. Completion rates were high (94.2%), with scores normally 
distributed, and no floor/ceiling effects. Test-retest reliability was excellent, and convergent validity 
strong (correlations 0.81-0.88). 
Conclusion 
A new musculoskeletal outcome measure has been developed, through a co-production process 
with patients to capture prioritised outcomes for use throughout the pathway and with different 
musculoskeletal conditions. Four validation cohorts found the MSK-HQ had high completion rates, 
excellent test-retest reliability, and strong convergent validity with reference standards. Further 
validation studies are ongoing, including a cohort with rheumatoid/inflammatory arthritis. 
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Strengths and limitations of this study  
• A new musculoskeletal health questionnaire (MSK-HQ) has been successfully developed 
through a co-production process with patients 
• The MSK-HQ captures key outcomes that were shown to be highly relevant to patients 
across a range of musculoskeletal conditions and settings  
• Promising measurement properties were found in four different musculoskeletal cohorts, 
with high completion rates, excellent test-retest reliability, and strong convergent validity 
with reference standards  
• Limitations of the study were the lack of a rheumatoid/inflammatory arthritis validation 
cohort, and that the MSK-HQ’s responsiveness has yet to be tested  
 
Introduction 
Taken together, osteoarthritis, inflammatory disorders and common musculoskeletal conditions 
such as back, neck, shoulder, hip and knee pain now represent the single greatest cause of years 
lived with disability.(1) Finding ways to prevent this impact on quality of life from increasing is a 
significant and important challenge.(2) In the UK these conditions are primarily managed in primary 
care, with referral to interface clinics and secondary care for more complex management or 
specialist treatment and surgery such as rheumatology or joint replacement. Until recently many 
musculoskeletal services have been provided within distinct, discrete silos of care, that have failed 
to address the long-term nature of these conditions or the fact that many patients have multiple 
musculoskeletal complaints in more than one region of the body.(3-5) Evidence exists for a wide 
variation in service performance, with a lack of consistency and continuity of care across the clinical 
pathway and poor adherence to the National Institute of Health and Care Excellence’s (NICE) 
Quality Standards of Care for musculoskeletal conditions.(6, 7) Current outcome tools and data 
collection systems are disparate and fragmented across different healthcare settings, and as a 
consequence, although many healthcare commissioners are aiming to re-orientate services from 
their traditional focus on acute and episodic care towards better prevention, self-care and 
integrated primary care,(8) there is a lack of clinical tools that link together different parts of the 
clinical pathway.   
Patient reported outcome measures (PROMs), which are short self-completed questionnaires 
designed to capture patient views about their health status,(9) are ideally suited to areas such as 
musculoskeletal health where disease impact is not easily captured using biomarkers. PROMs are 
therefore increasingly valued for their use in evaluating the performance of musculoskeletal 
services alongside measures of patient safety, patient experiences, and service indicators. One 
example of the ability of PROM data to act as a catalyst for raising standards has been evidenced 
through the UK’s National PROMs Programme which provides online reports(10) identifying the 
worst and best healthcare providers for four high-cost surgical procedures (hip and knee 
replacement, varicose vein removal and hernia repair). Building on early successes from this 
initiative there have been growing calls for new and practical musculoskeletal PROMs that can 
measure musculoskeletal health status across the pathway and across different pain problems. The 
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vision is for the routine and systematic use of a single musculoskeletal PROM throughout different 
parts of the service to drive forward quality improvement and ensure exemplar services are 
identified and emulated. 
The overall aim of this project was to develop and validate a new musculoskeletal PROM: the 
Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ). Pre-requisites for this MSK-
HQ were: it should be co-produced with patients and clinicians to identify aspects of health that 
were meaningful to both; it should aim to provide a holistic view of the impact on a person’s 
musculoskeletal health throughout the clinical pathway, and be applicable for use by different MSK 
health professionals; it should be generic across different MSK conditions and help identify 
individual treatment targets; it should be sensitive to change to enable longitudinal measurement 
and the monitoring of changes over time; it should demonstrate robust psychometric properties; 
and finally it should be easily interpretable and feasible for use in routine, busy clinical practice.  
In this study we address the following three objectives; 1) identifying and prioritising key outcomes 
to include in the MSK-HQ, 2) developing the draft MSK-HQ through a process of face and content 
validity testing, and 3) the initial validation study to report the MSK-HQ’s scoring, completion rate, 
test-retest reliability, convergent validity and internal consistency in both primary and secondary 
care musculoskeletal cohorts.    
 
Methods 
Objective 1: identifying and prioritising key outcomes to include in the MSK-HQ  
Scoping exercise:  
A brief scoping exercise was conducted by an experienced systematic reviewer to identify health 
outcome domains highlighted within primary and secondary research used to describe disease 
impact and characterise improvement for patients with arthritis, inflammatory conditions and 
musculoskeletal pain. Intervention studies were searched on the Medline database from 1st 
January 2000 to 1st December 2013, and data extracted using the following headings: author, date, 
clinical setting, domains used to characterise patients, and the primary outcome. The purpose of 
this exercise was to identify a list of potentially relevant outcomes to inform the following 
consensus process.  
Consensus Workshop: 
A consensus workshop with stakeholders from the UK musculoskeletal community was held to 
identify and prioritise key musculoskeletal outcome domains for inclusion in the MSK-HQ. 
Stakeholders (n=29) in attendance included patients (n=8; from primary care, orthopaedic and 
rheumatology services), clinicians (n=7; including General Practitioners (GPs), physiotherapists, 
orthopaedists, rheumatologists and pain specialists), national musculoskeletal patient and 
professional body representatives (n=10), and musculoskeletal researchers (n=4). All participants 
provided informed written consent and patient representatives were remunerated in line with 
INVOLVE guidance.(11) The workshop used a nominal group technique(12) with patients having an 
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equal voice. Initially a study presentation was given including information on the outcome domains 
identified from the literature review. Then small group discussions (including a dedicated patient 
group) were held to identify potential domains for inclusion, followed by a full group discussion, 
and blind vote to retain domains with broad consensus (defined as >50% of participants). Lastly, 
individual participants ranked a final list of domains. Participants were also asked to discuss the 
maximum number of items within the MSK-HQ and the type of response options it would include.  
Objective 2: developing the draft MSK-HQ through a process of face and content validity testing 
Face-validity and content-validity testing:  
Having obtained a final list of prioritised musculoskeletal outcome domains, single items for each 
domain were formulated using relevant existing outcome domain questionnaires, expertise within 
the team and an iterative process with patients to optimise the wording of items and to ensure 
each question appropriately captured its respective prioritised domain (content validity). The 
formal iterative process to improve the MSK-HQ’s face- and content-validity involved holding four 
focus groups, with six individual patients. The first two focus groups were held at Keele University 
with three patients, two of whom had osteoarthritis and the third had back pain. The next two 
focus groups were held at Oxford University with three patients, one with rheumatoid arthritis, and 
two with experience of orthopaedic surgery (hip and knee). In addition, before and after each 
workshop the MSK-HQ was iteratively improved through a cognitive interview with each of the six 
patients using a combination of verbal probing and think aloud methods(13) to establish the tool’s 
acceptability, feasibility, comprehension, readability, and perceived responder burden.  
Stakeholder acceptability: 
To determine the MSK-HQ’s acceptability to the wider musculoskeletal community, a second 
workshop with the same stakeholders involved in the first consensus workshop was held to present 
the final candidate MSK-HQ prior to psychometric testing. A blind vote was used to confirm 
whether the stakeholders agreed the measure was acceptable for validation testing (>80% 
agreement required) and to agree the context in which the MSK-HQ should and should not be used. 
The culmination of this process was a candidate MSK-HQ ready for psychometric testing.  
Objective 3: Initial measurement properties of the MSK-HQ 
Design and setting: 
1) Community physiotherapy cohort:   
A cross-sectional validation cohort was derived from consecutive consulters in community 
musculoskeletal physiotherapy clinics in five UK West Midlands towns (Middlewich, Congleton, 
Wombourne, Cheadle, and Wolverhampton). These clinics provide individual, face-to-face 
treatments within the English National Health Service (NHS) for patients referred from their GP. 
Participants received usual physiotherapy care according to clinical need. Consecutive adult (>=18 
years) consulters with a musculoskeletal disorder were invited to participate having received a 
study information pack with their community physiotherapy appointment. No further 
inclusion/exclusion criteria were used except that patients had to be referred to the clinic by their 
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GP, with the expectation that the cohort would comprise patients with a heterogeneous range of 
diagnostic groups and unspecified presenting musculoskeletal problems. Participants completed 
the MSK-HQ and other measures before the start of treatment at the first clinic and again at the 
second visit (typically 2 weeks later) to investigate test-retest reliability of the tool. 
2) Secondary care orthopaedic cohorts:  
Three validation cohorts were recruited from the Nuffield Orthopaedic Centre in Oxford by 
introducing the MSK-HQ into routine questionnaires used in the assessment pathway for patients 
listed for orthopaedic surgery for the knee, hip and shoulder. Adult participants (>=18 years) 
completed a standard set of questionnaires at their pre-operative assessment clinic and a subset 
completed the MSK-HQ approximately five days later at home for MSK-HQ reliability testing.  
Population descriptors: Baseline population descriptors were measured consistently across cohorts 
and included measures of demographic data (age, gender, work status) and pain characteristics: 
pain related days off work over past three months, pain episode duration, number of pain related 
visits to their GP in past 3 months, and outcome expectations (using a numerical response scale 
from 0 ‘it will get worse’ to 10 ‘it will be cured’.  
Reference standard measures of construct validity: All patients completed questionnaires containing 
the candidate MSK-HQ and the EQ-5D-5L.(14) The EQ-5D-5L utility score was calculated using the 
UK Crosswalk value set.(15) In addition, the orthopaedic cohort patients completed the Oxford Hip 
Score (OHS), Oxford Knee Score (OKS), Oxford Knee Score-Activity & Participation Questionnaire 
(OKS-APQ) and Oxford Shoulder Score (OSS) for respectively, hip, knee and shoulder problems and 
the physiotherapy cohort completed the six item Keele MSK-PROM.(16) 
Test retest reliability 
To identify patients with stable symptoms, when patients completed the second MSK-HQ for test 
retest reliability assessment they also completed a patient global rating of improvement question, a 
recommended core outcome in chronic musculoskeletal and osteoarthritis trials.(17) The item 
asked “Overall compared to the start of treatment, my symptoms are: much better, better, same, 
worse, or much worse”. Stable patients were defined as those who reported their symptoms were 
the ‘same’ at retest. 
Scoring the MSK-HQ 
To ensure simplicity of the MSK-HQ scoring, which stakeholders emphasised was important during 
the consensus workshops, scores from all 14 items are summed together (responses coded from 
‘not at all’ = 4 to ‘extremely’ = 0, except for items 12 and 13 which have the response options in the 
reverse order) providing a range from 0-56, with higher scores indicating better MSK health status.  
Statistical analysis  
MSK-HQ acceptability was assessed using response rates and completeness of data by examining 
the normal distribution of MSK-HQ scores and floor and ceiling effects (<10% threshold). Complete 
case analyses were performed throughout the analyses for the MSK scores, with no imputation for 
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missing values. A person-item map for a partial credit Rasch model was performed in order to build 
a hypothetical unidimensional line along which items and persons are located according to their 
difficulty and ability.(18) 
The MSK-HQ items were tested for internal consistency using Cronbach’s alpha to establish whether 
items may be treated as a single additive scale using both baseline and retest data. The Standard 
Error of the Mean (SEM) was calculated using SD × �(1− 𝑅𝑅). (19) 
 
To examine test retest reliability, between MSK-HQ scores at baseline and retest Kendall’s 
coefficient of concordance (W) was calculated to examine individual item agreement,(20) and the 
Intra-class Correlation Coefficient (ICC - based on a two-way random effect, absolute agreement 
model) was used to test overall score agreement in the combined dataset and as a sensitivity 
analysis for each individual cohort. An ICC above 0.70 is considered acceptable/good.(21) 
To examine the convergent validity of the MSK-HQ against reference standard measures we used 
both Pearson and Spearman correlations between sum scores at baseline.(21) The a priori 
hypothesis was that the MSK-HQ total score (higher = better) would follow a similar response 
pattern to those on reference standard scales. 
The sample size for each validation cohort was calculated from the minimum number of patients 
recommended to investigate MSK-HQ test retest reliability among a conservatively estimated 30% 
reporting stable symptoms. Using the Donner & Eliasziw(22) approach for estimating sample size 
for reliability testing we calculated that 102 people were needed for the physiotherapy cohort and 
orthopaedic cohorts combined, to detect a minimum acceptable ICC of 0.70, assuming a true ICC of 
0.80, with a power of 80% and 5% significance level.  
All analyses were conducted in STATA/IC v14 (StataCorp LP., 2015), SPSS v22 (IBM Corp., 2013) and 
Statistical software-R v3.2.2 (The R Foundation for Statistics, 2015). 
 
Results  
Objective 1: identifying and prioritising key outcomes to include in the MSK-HQ  
Scoping review and consensus workshop:  
The brief scoping review produced a list of over 75 existing outcome domains (available from the 
authors on request) from the literature. This was presented at the consensus workshop. Following 
the consensus process, participants identified and prioritised the following key outcomes for 
inclusion in the MSK-HQ (in priority order): severity of pain/stiffness (in the day and night), physical 
function (walking and dressing), physical activity level, pain interference (with work/daily routine 
and with social activities/hobbies), difficulty with sleep, fatigue/low energy levels, emotional well-
being (anxiety and mood), understanding of diagnosis and treatment, confidence to self-manage 
(pain self-efficacy),  independence, and overall impact from symptoms. There were no marked 
differences in domain preferences between patients, clinicians and other stakeholders, and at the 
conclusion of the process there was strong endorsement across the stakeholder community for the 
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key domains that emerged. It was agreed that the MSK-HQ should include no more than 15 items 
and would use a response scale based on Likert ‘severity’ response options. 
Objective 2: developing the draft MSK-HQ through a process of face and content validity testing 
A summary of the patients’ feedback about the face-validity, content-validity, recall period, 
response scale, format and layout, sensitivity to change, and application of the MSK-HQ is provided 
in Table 1.  
On average the MSK-HQ took around two minutes to complete. The MSK-HQ Flesch reading ease 
test score is 65.9 meaning it is easily understood by 13-15 year old students, and is easier to read 
than many PROMs such as the EQ-5D-5L which scores 61.3.  
The MSK-HQ is available online via General Info: http://isis-innovation.com/health-outcomes/ and a 
Licence request: http://process.isis-innovation.com/ 
Examples of the MSK-HQ items are provided in Figure 1. 
Figure 1 here 
Objective 3: Initial measurement properties of the MSK-HQ  
Study sample 
There were 570 patients in total who consented to participate in the four studies (210 
physiotherapy patients, 150 hip, 150 knee, 60 shoulder). Baseline population characteristics for the 
overall sample and for each cohort are summarised in Table 2, showing a mean age of 56.99 years 
(SD 16.54) with 65.19% female. The median pain episode duration was 6.58 months (SD 4.42), and 
the mean EQ-5D-5L utility score was 0.49 (SD 0.26).  
Table 2 here 
MSK-HQ Acceptability/completion rates: 
The MSK-HQ was acceptable to patients, with complete MSK-HQ data available for 537/570 
patients (94.2%). Across the Hip, Physiotherapy, and Shoulder cohorts there was around 3% missing 
data (see Table 2) but the proportion of missing data was substantially higher in the Knee cohort at 
14.7%, as data entry was not checked in clinic. In data for the four cohorts combined, the best 
completed MSK-HQ item was the ‘walking’ (item 3) with 4/570 (0.07%) missing responses, whilst 
the ‘fatigue/low energy’ (item 10) had the most missing responses 9/570 (1.6%). Within the knee 
cohort (n=150) missing responses were higher than for other cohorts but were spread fairly evenly 
across all 14 MSK-HQ items varying from 3/150 people (2%) for the ‘walking’, ‘social activities’, and 
‘sleep’ items, to 7/150 people (4.7%) for the ‘understanding of condition’ item. The person-item 
map for a partial credit Rasch model revealed that across the combined cohorts the most difficult 
item to get a lower severity score was ‘overall impact’ (item 14), and that ‘washing/dressing’ (item 
4) was the easiest item to get a lower severity score (see Figure 2). No weighting was given to any 
items in order to ensure that the MSK-HQ is simple to use and interpret in clinical practice. The 
MSK-HQ scores for all the cohorts combined were normally distributed with an overall mean score 
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of 28.62 (9.61) from a possible range of 0-56. No floor or ceiling effects were observed. Within the 
four cohorts the Hip cohort had the worst overall MSK health status with a mean (sd) MSK-HQ total 
score of 24.93 (8.27). Overall MSK health status was about 3 points more favourable across each of 
the other three cohorts with mean (sd) MSK-HQ scores for Knee, Physiotherapy and Shoulder 
cohorts being 27.54 (9.03), 30.54 (9.56), and 33.48 (10.54) respectively. The SEM for the MSK-HQ 
was 5.52.  
Figure 2 here 
Internal consistency 
Analysis of internal consistency demonstrated the total score can be adequately considered as one 
scale, with a mean Cronbach’s alpha at baseline of 0.88. Alpha values for each individual item were 
similar and are provided in Table 3. The item on ‘interference with work/daily routine’ was the most 
correlated item to the total MSK-HQ score (0.76) and responses for two items (understanding your 
condition and confidence to self-manage) were shown to correlate weakly (-0.04 and 0.32 
respectively) with the total MSK-HQ score. The retest data showed similar patterns of results. 
Table 3 here  
Test-retest reliability 
There were 370/537 patients (70.0%) with retest MSK-HQ data available with a mean (sd) time 
interval of 5.92 (4.63) days). There were 245 (66.2%) patients reporting ‘stable’ symptoms between 
the two time-points, with 73 (19.8%) reporting being ‘better’ and 52 (14%) ‘worse’. Within the 
group with ‘stable’ symptoms, the MSK-HQ total score agreement ICC was 0.84 (95% CI 0.77 – 0.89, 
n=226), demonstrating ‘excellent’ reliability. The sensitivity analysis for each individual cohort 
revealed the ICC within the Hip cohort was 0.91 (95% CI 0.85 – 0.95, n=60); Knee cohort was 0.79 
(95% CI 0.67 – 0.87, n=63); Physiotherapy cohort was 0.80 (95% CI 0.45 – 0.91, n=79); and Shoulder 
cohort was 0.93 (95% CI 0.84 – 0.97, n=24). Kendall’s coefficient of concordance for individual item 
agreement in the combined dataset ranged from 0.72 for the ‘understanding of condition’ and 
‘confidence in managing symptoms’ items, to 0.90 for the ‘sleep’ item. Details of inter-rater 
agreement for each of the 14 items are given in Table 3. 
Convergent validity 
The Pearson and Spearman's rank correlation of the MSK-HQ with the EQ-5D-5L for the overall 
combined data were strong, being 0.80 and 0.81 respectively. Table 4 demonstrates strong 
correlations between the MSK-HQ and reference standards for each of the four cohorts including 
the MSK-PROM, OHS, OKS and OSS, in particular with the OKS and OSS with Spearman’s of 0.88 and 
0.86 respectively. 
Table 4 here  
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Discussion: 
This study describes the successful development and initial psychometric validation of the MSK-HQ. 
This new outcome measure has been co-produced with patients and clinicians to measure the 
holistic impact of an MSK condition on a person’s health, regardless of the location of their MSK 
pain or where on the clinical pathway an individual is currently receiving care. The first phase of the 
project successfully identified and prioritised key outcomes that a broad range of MSK patients and 
clinicians ranked as the most important for identifying and monitoring the impact from an MSK 
condition on overall MSK health status. These domains included severity of pain/stiffness (both in 
the day and at night), physical function (walking and dressing), physical activity level, symptom 
interference (with work/daily routine and with social activities/hobbies), difficulty with sleep, level 
of fatigue/low energy levels, emotional well-being (anxiety and mood), understanding of diagnosis 
and treatment, confidence to self-manage (pain self-efficacy), independence, and overall impact 
from symptoms. The wording for single items to capture each of these domains was successfully 
optimised through a process of face and content validity testing with users, resulting in 14 items 
that patients with a range of MSK conditions felt were ‘highly relevant’ to their lives and ‘easy to 
understand’.  
Our validation study included 570 MSK patients from four different cohorts with a range of MSK 
conditions from both primary/community and secondary care settings. The results demonstrated 
that the MSK-HQ was well completed, has excellent test-retest reliability, and has strong 
convergent validity with reference standards. The findings were consistent across the four cohorts 
suggesting promising initial cross-sectional psychometric properties of the MSK-HQ. As might be 
expected, patients’ MSK health status (measured by the MSK-HQ total score) was shown to be 
worst among secondary care patients awaiting Hip surgery (mean = 24.93) and Knee surgery (mean 
= 27.54), and was less severe among those receiving community physiotherapy (mean = 30.54). 
Whilst the MSK-HQ is a multi-dimensional measure its high internal consistency across items 
(Cronbach’s alpha of 0.88) suggests it can be considered as one scale for overall MSK health status 
with the MSK-HQ total score. To ensure simplicity of the MSK-HQ scoring in routine clinical practice, 
which emerged as important during the consensus workshops, scores from individual items are 
summed together, providing a range from 0-56. The MSK-HQ overall score is not a score of a single 
construct (reflective model), but a sum of items from different domains measuring overall 
musculoskeletal health status (formative model). Alternative scoring approaches including 
weighting items were discussed at the second stakeholder workshop and it was agreed that firstly, 
a non-weighted approach was better suited to using the tool in routine practice, and secondly that 
the provision of a single additive scale was clinically useful in helping to evaluate the overall impact 
of the musculoskeletal condition on the individual. The study identified that the test-retest 
reliability of the MSK-HQ’s total scores among ‘stable’ patients between the baseline and retest 
time-points (using ICCs) was ‘excellent’ overall. In addition, as a sensitivity analysis we examined the 
test-retest reliability separately for each of the four cohorts, which found that the ICC varied from 
0.79 to 0.93. It should be noted however, that it is unwise to use these figures to directly compare 
the reliability of the tool in the different cohorts due to the potential for bias, as the study was not 
powered for this sensitivity analysis and the proportion of ‘stable’ patients differed across the four 
cohorts. Finally, the strong correlations with different single MSK condition reference standards, 
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particularly with the Shoulder, Knee and Hip cohort reference standards (OSS=0.86, OKS=0.88 and 
OHS=0.83) shows the potential for the MSK-HQ to capture overall MSK health status across 
different MSK conditions instead of relying on existing condition-specific measures. 
In order for healthcare services and individuals with MSK conditions to better manage and monitor 
their own health, appropriate clinical tools are required that can capture the overall impact from 
fluctuating symptoms.(23) Previous research has sought to identify key outcome domains for 
different musculoskeletal conditions, but have not sought to have one list of outcome domains that 
can capture the overall impact for all MSK conditions. For example, work in 1998 by Deyo and 
colleagues,(24) recommended the following core outcome domains for low back pain disorders: 
pain (severity and frequency), back-related function, generic well-being, difficulty with social 
role/work, and patient satisfaction with care. In 2014, four more domains were added to this list: 
pain interference, depression, sleep disturbance, and catastrophising.(25) For patients with 
osteoarthritis, recommended outcome domains include: pain, functional impairment and patient’s 
global assessment of change.(26-28) Separately, the International Classification of Functioning, 
Disability and Health has made individual recommendations for different MSK conditions such as 
low back pain, chronic widespread pain, ankylosing spondylitis, osteoporosis, osteoarthritis, and 
rheumatoid arthritis with the most common domains across conditions being symptom severity 
(pain intensity), function (physical function, social function, work function), generic well-
being/quality of life, patient’s global assessment of change, emotional functioning, independence, 
and patient satisfaction.(29) It can be seen that the domains included in the MSK-HQ are largely 
consistent with all of the above recommendations although the MSK-HQ does not measure 
domains such as patient satisfaction or global assessment of change which are typically captured at 
a single post-treatment time-point and not longitudinally over time.    
A key vision of the MSK-HQ was to fill the current gap for a single broad health status measure 
instead of relying upon generic health tools such as the EQ-5D-5L which have been shown to be less 
sensitive to change in MSK populations.(16) One key requirement for the MSK-HQ yet to be tested, 
is whether it is more sensitive to change than the EQ-5D-5L. Follow up data is currently being 
collected, to be reported separately in due course. Such a tool would have strong potential in 
helping to overcome current challenges in driving forward MSK health service improvements 
caused by the use of so many different PROMs across the pathway, despite a common entry point 
for different MSK conditions. The use of the MSK-HQ as a standard summative PROM across the 
MSK pathway is initially supported by the results of this study, although further research to 
examine the responsiveness and applicability of this tool in other musculoskeletal patient 
populations is recommended.(30) 
In many long-term conditions, such as diabetes or asthma, PROMs are also used to guide 
treatment. This too was part of the vision for the MSK-HQ, to capture an individual’s MSK health 
status at any given time and thereby enable patients and their clinicians to monitor progress over 
time and response to treatment. Individual MSK-HQ items capturing ‘sleep’, or ‘physical activity’ 
could also enable specific patient needs to be tracked over time and support the reporting of key 
issues to clinical teams thereby facilitating better shared decision-making in consultations. Further 
strengths of the MSK-HQ are its co-production with patients, using domains which have high face 
validity, are easy to understand as well as being reliable and valid in heterogeneous MSK 
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populations. However, a clear weakness of this study is the lack of a rheumatology or pain clinic 
validation cohort, although separate work is in progress to test the MSK-HQ within a rheumatology 
setting and data should be available soon. Another weakness is that missing item rules and minimal 
clinically important differences are not yet available for this measure, although future studies will 
seek to address these issues. It is interesting to note that MSK-HQ completion rates were below, or 
at, 3% when the tool was completed and checked in clinic, but were nearly 15% in the knee cohort 
where patients completed the tool unsupervised at home. It will be important for future studies to 
test whether electronic data capture rather than the paper based questionnaires used in this study, 
is able to reduce the number of missing items in contexts where the tool is completed 
unsupervised. 
Important next steps for this research are to examine the factor structure of the MSK-HQ as well as 
its responsiveness in comparison to condition specific measures such as the Oxford Hip and Knee 
Scores and generic health status measures such as the EQ-5D-5L. Future research opportunities for 
the MSK-HQ include its potential to help in reviewing patients MSK health status in primary care 
chronic disease review clinics, and testing its usefulness as a consultation prompt and care planning 
tool to shape musculoskeletal consultation conversations and ensure individual issues are 
addressed. 
 
Conclusion: 
A new PROM for a broad range of MSK conditions has been successfully developed, called the MSK-
HQ. This novel PROM contains 14 items that capture key outcomes that patients with a range of 
MSK conditions have prioritised as important for use across the clinical pathway. The MSK-HQ has 
also undergone initial psychometric testing in four different MSK cohorts and demonstrated high 
completion rates, excellent test-retest reliability, and strong convergent validity with reference 
standards including the EQ-5D-5L, and Oxford Hip, Knee and Shoulder scores. Ongoing follow-up 
studies will examine the responsiveness and factor structure of the MSK-HQ in the future. 
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Table 1: Summary of patient feedback 
General 
qualities 
Patient Feedback 
Face validity • Patients felt most questions were relevant, easy to understand and answer 
• Patients tended to interpret the questions correctly as they were intended 
• Some queried if the MSK-HQ may be difficult for individuals with multiple MSK conditions e.g. 
'which condition do I talk about?'  
Content 
validity  
• Patients considered that all items were highly relevant and important to their daily lives 
• Patients agreed that the MSK-HQ covered most prioritised domains they wanted 
• Other domains suggested included: 
o severity of and/or length  of time with stiffness during the day and at night 
o Effectiveness of pain relief treatments/therapies 
o Impact on social activities  
o A general change in health question 
Recall period • Patients correctly used a two-week recall period for most questions  
Response 
scale 
• All patients generally agreed the response scale & descriptive responses were appropriate 
• The use of ‘extremely’ as the final response option was changed as it was not always appropriate 
Format and 
layout 
• Patients considered the layout and format to be appropriate  
• Some minor issues, included:  
o The MSK-HQ instructions and spacing of items 
o Response options descriptors should be close to tick boxes 
o Labelling of the items was improved 
• Patients did not generally notice the scoring codes for each item response. A few mentioned that 
they are used to see these on questionnaires and did not think it was a problem having them 
included 
Sensitivity to 
change 
• Patients suggested that all domains were likely to change over time, depending on stage or 
severity of their condition: 
o Domains most likely to change: walking, pain, sleep, physical activities, impact 
o Domains least likely to change: dressing, help needed 
Application 
and 
administration 
• Patients thought the MSK-HQ would be useful to monitor health regularly 
• The generic nature of the questionnaire was mostly perceived to be a positive thing so it can be 
used across different MSK conditions 
• Patients suggested they would be happy to complete it themselves at home. Completion every 
three months was suggested as a suitable follow-up period.  
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Table 2: Baseline characteristics overall and by each cohort (values represent mean (standard deviation) 
unless otherwise indicated) 
Variable All 
participants 
n=570 
Physio 
n=210 
Hip 
n=150  
Knee 
n=150  
Shoulder 
N=60  
Demographic variables      
Age (years) 56.99 (16.54)  53.53 (15.45) 55.62 (17.21) 65.68 (13.80) 51.54 (17.15) 
Sex, n (%) female 313 (65.19) 112 (53.59) 88 (60.69) 89 (62.24)  24 (40.00) 
Employment status, n (%) 
yes working 
263 (48.88) 126 (60.29) 64 (45.07)  40 (30.53) 33 (58.93) 
Taken time off work for 
pain, n (%) 
56 (21.29) 27 (21.42) 15 (23.43)  8 (20.00) 6 (18.18) 
Pain duration (months) 6.58 (4.42) 4.84 (2.95) 8.41 (5.76) 8.16 (4.69) 9.13 (4.13) 
No. of pain related visits to 
GP, past 3 months 
1.39 (1.45) 1.53 (0.93)  1.47 (2.05) 1.37 (1.45) 0.73 (0.99) 
Outcome expectations 
(NRS) 
9.25 (1.63) 8.38 (1.77) 9.82 (1.18) 9.79 (1.27) 9.67 (1.56) 
Clinical variables      
MSK-HQ total score1  28.62 (9.61)          30.54 (9.56)          24.93 (8.27)              27.54 (9.03)            33.48 (10.54)   
EQ-5D-5L Utility score 0.49 (0.26)       0.55 (0.25)       0.40 (0.24)    0.45 (0.26)           0.56 (0.25) 
Keele MSK-PROM  17.44 (4.45)    
Oxford Hip Score    20.4 (8.62)   
Oxford Knee Score     20.89 (8.84)  
Oxford Shoulder Score      29.62 (10.34) 
Missing data for MSK-HQ score1:  All participants n=33 (5.8%), Physio cohort n=5 (2.4%), Hip cohort n=4 
(2.7%), Knee cohort n=22 (14.7%), Shoulder cohort n=2 (3.3%) 
NRS – numerical rating scale; MSK-HQ – Musculoskeletal Health Questionnaire, EQ-5D-5L – EuroQol 5 level,  
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Figure 1 – Example items from the Musculoskeletal Health Questionnaire (MSK-HQ) 
 
Figure 2: A person-item map for the Rasch partial credit model presents item response difficulty 
 
Table 3: Internal consistency of the MSK-HQ at baseline and retest 
 Item 
 
Baseline (n=537) Retest (n=376) Baseline and 
Retest 
Mean  (SD) ritem-
rest= 
α= Mean (SD) ritem-
rest= 
α= N Kendall's 
W 
MSK-HQ Total [0, 56]    0.88    0.92 358 0.91  
1. Pain/stiffness during the day 1.52 (0.91) 0.69 0.87 1.71 (0.89) 0.76 0.91 379 0.83  
2. Pain/stiffness at night 1.65 (1.09) 0.60 0.87 1.96 (1.12) 0.65 0.92 379 0.87  
3. Walking 2.11 (1.16) 0.57 0.88 2.23 (1.18) 0.69 0.91 380 0.89  
4. Washing/Dressing 2.77 (1.02) 0.60 0.87 2.89 (0.97) 0.64 0.92 382 0.86  
5. Physical activity levels 1.52 (1.14) 0.56 0.88 1.72 (1.29) 0.70 0.91 379 0.83  
6. Work/daily routine 1.81 (1.03) 0.76 0.87 2.11 (1.04) 0.81 0.91 381 0.83  
7. Social activities and hobbies 1.80 (1.11) 0.63 0.87 2.09 (1.17) 0.74 0.91 381 0.82   
8. Needing help 2.62 (1.21) 0.65 0.87 2.70 (1.19) 0.73 0.91 380 0.88  
9. Sleep 1.73 (1.28) 0.56 0.88 1.97 (1.35) 0.60 0.92 382 0.90  
10. Fatigue or low energy 2.22 (1.08) 0.63 0.87 2.27 (1.07) 0.71 0.91 381 0.87  
11. Emotional well-being 2.47 (1.16) 0.64 0.87 2.65 (1.12) 0.70 0.91 382 0.84  
12. Understanding condition  2.60 (1.10) -0.04 0.90 2.95 (0.80) 0.10 0.93 379  0.72  
13. Confidence in managing 2.39 (0.99) 0.32 0.89 2.50 (0.94) 0.41 0.92 382 0.72   
14. Overall impact 1.42 (0.88) 0.74 0.87 1.59 (0.96) 0.79 0.91 381 0.82  
n = Number of individuals with complete scales 
ritem-rest=The correlation between an item and the scale that is formed by all other items.  
α=Cronbachs alpha of the scale excluding all but one of the items, except where "Total" indicates Cronbachs alpha for complete scale. 
 
 
Table 4: Convergent construct validity - Correlations between reference standards 
 
 
  Comparator Index  Baseline 
N Spearman 
Correlation 
Pearson 
Correlation 
s=(95% CIs) r=(95% CIs) 
MSK Total [0,56] OHS [0,48] Hip 130 0.83 (0.77 , 0.88) 0.83 (0.77 , 0.88) 
 OKS [0,48] Knee 125 0.88 (0.83 , 0.91) 0.89 (0.84 , 0.92) 
 OSS [0,48] Shoulder 53 0.86 (0.78 , 0.92) 0.87 (0.79 , 0.93) 
MSK Total [0,56] EQ-5D-5L Index [-0.59,1] Total 525 0.81 (0.78 , 0.84) 0.80 (0.76 , 0.83) 
  Hip 141 0.76 (0.68 , 0.82) 0.77 (0.69 , 0.83) 
  Knee 123 0.78 (0.70 , 0.84) 0.75 (0.67 , 0.82) 
  Shoulder 58 0.84 (0.74 , 0.90) 0.81 (0.70 , 0.89) 
  Physio 203 0.82 (0.77 , 0.86) 0.81 (0.76 , 0.85) 
MSK Total [0,56] MSK-PROM [0,30] Total 203 0.81 (0.75, 0.85) 0.82 (0.77, 0.86) 
 
 
